Gessel has advised Pure Biologics and its shareholder Filip Jelen on an investment from Michal Lach. DZP advised Michal Lach.
Pure Biologics is a Warsaw Stock Exchange-listed biopharmaceutical company that operates in the field of immuno-oncology, autoimmunity, and neurological rare diseases, conducting research using technological platforms for the selection of active particles – antibodies and aptamers.
According to Gessel, the investment included the sale of a block of shares in the company by Jelen to Lach, coupled with Jelen’s "reinvestment of the proceeds from the sale back into the company. Additionally, the transaction terms define the terms of the investor's capitalization of the company to finance key projects in the field of immuno-oncology."
In 2023, Gessel advised Pure Biologics on a PLN 12 million investment from ACRX Investments (as reported by CEE Legal Matters on June 29, 2023) and on its public offering of shares (as reported by CEE Legal Matters on January 5, 2023).
The Gessel team included Managing Associate Michal Wielinski and Junior Associate Antonina Stepniewska.
The DZP team included Partner Maciej Zajda, Counsel Maciej Goszczyk, and Associate Margarita Kobojek.
